News by Tag: Us Dyslipidemia Market
Despite an Increasing Volumes, the US Dyslipidemia Market to Decline by a CAGR of 10% during 2010-2016
September 26, 2011
A new report from IMARC Group expects the US dyslipidemia market to decrease by value in the coming years.
September 26, 2011
A new report from IMARC Group expects the US dyslipidemia market to decrease by value in the coming years.
New Reports From EMR Provide a Comprehensive Insight on the Potential of Dyslipidemia Drugs in Key Developed Markets
September 2, 2011
EMR's latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key developed dyslipidemia drug markets till 2016.
September 2, 2011
EMR's latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key developed dyslipidemia drug markets till 2016.
Generics to account for more than 92% of the US Dyslipidemia market by 2016
August 22, 2011
A new report from IMARC Group expects the volume share of generic drugs in the US Dyslipidemia market to reach levels worth more than 92% by 2016.
August 22, 2011
A new report from IMARC Group expects the volume share of generic drugs in the US Dyslipidemia market to reach levels worth more than 92% by 2016.